News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Sunrun priced a $267 million securitization of residential solar leases and power purchase agreements.
  • The transaction is Sunrun's seventeenth securitization since 2015.
  • Pricing improved versus Sunrun's prior issuance, signaling stronger investor demand for solar assets.
  • The deal is backed by over 37,000 systems across 13 U.S. states.
  • The securitization is expected to close by the end of August.
  • Proceeds will strengthen Sunrun's capital structure and fund future residential renewable deployments.

Latest Articles

NVIDIA Pullback: Buy the Market Leader While Growth Still Priced In

NVIDIA Pullback: Buy the Market Leader While Growth Still Priced In

Nvidia is trading ~7% off its 52-week high after a sharp two-day pullback. The business fundamentals remain intact - enormous free cash flow, industry-leading returns on equity, and near-zero net leverage - while technicals show the stock finding support near its 20/50-day moving averages. This trade targets a measured rebound to $230 with a tight …

Esperion to be Acquired by ARCHIMED

Esperion to be Acquired by ARCHIMED

Esperion Therapeutics, a biopharmaceutical company specializing in cardiometabolic and rare disease therapies, agreed to be acquired by ARCHIMED in a transaction worth up to $1.1 billion. Esperion shareholders will receive $3.16 per share in cash plus potential milestone payments tied to future sales. The deal offers a significant premium and posit…

MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

MapLight Therapeutics, a clinical-stage biopharmaceutical company focused on central nervous system disorders, announced the completion of enrollment in the ZEPHYR Phase 2 trial for schizophrenia and the final patient visit in the IRIS Phase 2 trial for autism spectrum disorder. The company expects topline results from both trials by mid-August 202…

OIO Group Announces New Leadership, Board Appointments and Strategic Roadmap for Ultra-Luxury Mobility Platform

OIO Group Announces New Leadership, Board Appointments and Strategic Roadmap for Ultra-Luxury Mobility Platform

Following its business combination with De Tomaso Automobili, OIO Group announces its new board and executive team, outlining a strategy focused on ultra-luxury automotive marques, specialist engineering, and collector-driven programmes. The company aims to build a differentiated platform emphasizing rarity, craftsmanship, and brand authenticity to…

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

Molecular Partners announced the publication of positive Phase 1 clinical trial data for MP0317, a tumor-localized CD40 agonist, demonstrating effective tumor microenvironment modulation and a favorable safety profile in advanced cancer patients. The data support further clinical trials, including an ongoing Phase 2 study in cholangiocarcinoma, com…

Amazon: Take Profits Now, Plan to Buy the Next Real Pullback

Amazon: Take Profits Now, Plan to Buy the Next Real Pullback

Amazon remains one of the clearest long-term winners in cloud and retail, but the stock is materially overbought after a month-long rally. This trade idea lays out a disciplined plan: wait for a controlled pullback to enter, a tight stop to manage a momentum reversal, and a realistic mid-term target while keeping the long-term thesis intact.

Perella Weinberg Reports First Quarter 2026 Results

Perella Weinberg Reports First Quarter 2026 Results

Perella Weinberg Partners reported Q1 2026 revenues of $149 million, a 30% decline from last year, resulting in a GAAP pre-tax loss of $11 million. Despite lower revenues driven by fewer fee-paying clients and reduced deal closings, the firm made strategic acquisitions and expanded senior talent, including the addition of Gleacher Shacklock to incr…

Brookfield Renewable Reports Record First Quarter Results

Brookfield Renewable Reports Record First Quarter Results

Brookfield Renewable announced record first quarter 2026 financial results, including a 19% increase in Funds From Operations (FFO) year-over-year. The company highlighted the acquisition of Canadian renewable energy platform Boralex, adding substantial operating capacity and a large development pipeline. Growth driven by strong performance in hydr…

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced that the European Commission has authorized marketing of IMCIVREE® (setmelanotide) for treating obesity and controlling hunger in adults and children 4 years and older with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment. This follows FDA approval in the US and is based on Phase 3 TRANSCE…

Wabash Announces First Quarter 2026 Results

Wabash Announces First Quarter 2026 Results

Wabash National Corporation reported a 20.4% decline in first quarter 2026 revenue to $303 million, missing revenue guidance due to softer demand in the Truck Body segment. The company posted a GAAP operating loss of $52 million and a non-GAAP adjusted operating loss of $56 million. Despite operational inefficiencies and lower volumes, the Parts & …

Packed Markets, Fractured Central Banks and a Turbulent Energy Complex

Packed Markets, Fractured Central Banks and a Turbulent Energy Complex

This week delivered a dense slate of developments across central banks, energy markets and technology earnings. The Federal Reserve left its policy rate unchanged while its departing chair said he will remain at the Fed until "things have calmed down," and the meeting exposed an unusually high level of dissent. The Bank of Japan likewise recorded a…

Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution

Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution

Eton Pharmaceuticals has relaunched HEMANGEOL®, the only FDA-approved oral solution for treating proliferating infantile hemangiomas, with exclusive distribution through Anovo Specialty Pharmacy. The company has integrated its comprehensive Eton Cares program to provide $0 co-pay for eligible patients and expanded assistance, aiming to expedite the…

AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for First Quarter Fiscal 2026 Results

AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for First Quarter Fiscal 2026 Results

AirSculpt Technologies, a NASDAQ-listed company specializing in premium body contouring procedures, announced it will report its first quarter fiscal 2026 earnings on May 8, 2026, before market open. The company will follow the release with a conference call and webcast. Additionally, AirSculpt will participate in two investor conferences later in …

Deere elevates long-time executive Brent Norwood to CFO role

Deere elevates long-time executive Brent Norwood to CFO role

Deere has appointed Brent Norwood as its new chief financial officer effective May 1. Norwood, a 44-year-old internal candidate who most recently served as vice president and finance director for Construction and Forestry and John Deere Power Systems, succeeds Joshua Jepsen, who left in February. The company named an interim finance chief after Jep…

HF Sinclair Posts Unexpected Quarterly Profit as Refining Margins Rise

HF Sinclair Posts Unexpected Quarterly Profit as Refining Margins Rise

HF Sinclair reported an adjusted profit for the first quarter, reversing a year-earlier loss in its refining segment and beating analyst expectations, as U.S. refinery margins climbed amid disruptions to Middle Eastern oil flows that increased demand for U.S. fuel exports. The company recorded higher per-barrel refinery gross margins and a return t…